Evidence map›Paper›PMID 37936638›Full record

ArticleRSC advances2023

Design, synthesis and antiproliferative screening of newly synthesized coumarin-acrylamide hybrids as potential cytotoxic and apoptosis inducing agents.

Hany M Abd El-Lateef, Lina M A Abdel Ghany, Rasha Mohammed Saleem, Ali Hassan Ahmed Maghrabi, Maryam Abdulrahman Yahya Alahdal, Eman Hussain Khalifa Ali, Botros Y Beshay, Islam Zaki, Reham E Masoud

Open access · goldAbstract read
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Hany M Abd El-LateefDepartment of Chemistry, College of Science, King Faisal University Al-Ahsa 31982 Saudi Arabia hmahmed@kfu.edu.sa.
Lina M A Abdel GhanyPharmaceutical Chemistry Department, College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology 6th of October City Egypt.
Rasha Mohammed SaleemDepartment of Laboratory Medicine, Faculty of Applied Medical Sciences, Al-Baha University Al-Baha 65431 Saudi Arabia.
Ali Hassan Ahmed MaghrabiDepartment of Biology, Faculty of Applied Science, Umm Al-Qura University Makkah 24381 Saudi Arabia.
Maryam Abdulrahman Yahya AlahdalDepartment of Biology, Faculty of Applied Science, Umm Al-Qura University Makkah 24381 Saudi Arabia.
Eman Hussain Khalifa AliDepartment of Laboratory Medicine, Faculty of Applied Medical Sciences, Albaha University Saudi Arabia.
Botros Y BeshayPharmaceutical Sciences (Pharmaceutical Chemistry) Department, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport Alexandria Egypt.
Islam ZakiPharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Port Said University Port Said Egypt Eslam.Zaki@pharm.psu.edu.eg.ORCID https://orcid.org/0000-0002-2026-7373
Reham E MasoudClinical Pharmacology Department, Faculty of Medicine, Port Said University Port Said 42526 Egypt.
Al Baha University · SAPort Said University · EGUmm al-Qura University · SAArab Academy for Science, Technology, and Maritime Transport · EGKing Faisal University · SAMisr University for Science and Technology · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

On the basis of the observed biological activity of coumarin and acrylamide derivatives, a new set of coumarin-acrylamide-CA-4 hybrids was designed and synthesized. These compounds were investigated for their cytotoxic activity against cancerous human liver cell line HepG2 cells using 5-fluorouracil (5-FU) as a reference drug. Compound 6e had promising antiproliferative activity with an IC

Identifiers

PMID37936638
PMCPMC10626558
OpenAlexW4388413484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.